Targeted antibody, immune checkpoint blocker rein in follicular lymphoma Medical Xpress "The combination of the established antibody drug rituximab with the experimental drug pidilizumab so far also has a remarkably mild side effect profile," Neelapu said. Of 29 study participants at a median follow-up of 15.4 months, 19 (66 percent) had ... |
